Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by thisisriskystufon Oct 04, 2018 8:09am
170 Views
Post# 28742974

First full quarter of sales of Trogarzo{A ™}

First full quarter of sales of Trogarzo{A ™}Theratechnologies earns $367,000 in Q3 2018-10-04 07:49 ET - News Release Mr. Denis Boucher reports THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018 Theratechnologies Inc. has provided its financial results for the third quarter ended Aug. 31, 2018. Third quarter 2018 financial highlights Record third quarter net sales of $17,714,000, up 58% from the same quarter last year First full quarter of sales of Trogarzo{A ™} EGRIFTA trademark sales up 15% from the same quarter last year Positive EBITDA of $2,735,000 in the third quarter of 2018 compared to a negative EBITDA of $(2,046,000) for the same quarter last year1 Cash position of $66,490,000 at August 31, 2018
Bullboard Posts